2015’s top five mergers and acquisitions in a record-breaking year
October 19, 2015Sales and Marketing Deals, acquisitions, mergers, pharma, takeovers
A new report from analysts MergerMarket reveals that mergers and acquisitions so far in 2015 have surpassed the same 2014 …
Shire’s dry eye treatment gets a no – for now
October 19, 2015Sales and Marketing Complete Response Letter, FDA, Flemming Ornskov, Shire, dry eye disease, lifitegrast
Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …
FDA approves Boehringer’s Pradaxa reversal agent
October 19, 2015Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab
The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …
Sanofi and Regeneron heart drug Praluent available in UK
October 19, 2015Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent
Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …
FDA rejects AstraZeneca diabetes combination
October 16, 2015Research and Development, Sales and Marketing AstraZeneca, FDA, NDA, dapagliflozin, saxagliptin
The FDA has declined to approve AstraZeneca’s New Drug Application (NDA) for the investigational fixed-dose combination of Onglyza and and …
Pfizer’s Xeljanz denied plaque psoriasis indication by FDA
October 16, 2015Research and Development, Sales and Marketing FDA, Pfizer, Xeljanj, tofacitinib
The FDA has rejected the indication expansion of Pfizer’s Xeljanz (tofacitinib) for treatment of moderate to severe cases of plaque psoriasis. …
Top 10 US pharma advertising spenders, September 2015
October 16, 2015Medical Communications, Sales and Marketing
As a new study from TV advertising metrics company iSpot reveals the top 40 pharma companies spent $231 million on TV …
NICE to recommend three new treatments for hep C
October 16, 2015Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C
NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …
Ashfield UK makes two new business development appointments for its growing team
October 16, 2015Medical Communications Ashfield UK
Ashfield has appointed David Tweedale and Ian Robinson as Business Development Managers to the UK Commercial and Clinical business, located …
The Prime Medical Group expands senior team in New York City
October 16, 2015Medical Communications
The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …
Health apps now more popular than ever in the UK
October 16, 2015Medical Communications apps, digital pharma, health technology, technology
The use of health apps has considerably increased over the past years, according to a new survey that has found …
NICE requests more evidence on Duchenne muscular dystrophy therapy
October 16, 2015Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PCT Therapeutics, Translarna, ataluren
NICE has chosen not to recommend has PTC Therapeutics’ treatment Translarna for Duchenne muscular dystrophy (DMD), asking for further clarification …
The Prime Medical Group expands senior team in New York City
October 15, 2015Medical Communications The Prime Medical Group
The Prime Medical Group is pleased to announce several key appointments to its New York office as the company continues …
Valeant receives court writ over US drug pricing
October 15, 2015Medical Communications, Sales and Marketing Drug pricing, Isuprel, Nitropress, US, Valeant, subpoena
Valeant Pharmaceuticals has disclosed that it has received two subpoenas in the US, demanding evidence concerning the pricing and distribution …
$350m collaboration deal for BMS and Five Prime Therapeutics
October 15, 2015Research and Development BMS, Bristol-Myers Squibb, R&D, five prime, immuno-oncology, tumours
Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …
Ablynx and Merck begin immuno-oncology collaboration
October 15, 2015Research and Development Ablynx, Merck, immuno-oncology, nanobody, proof of concept
Ablynx has achieved a pre-clinical proof-of-concept with a nanobody construct as part of its immuno-oncology collaboration with Merck – triggering …
Allergan axes 117 jobs in Kythera buyout
October 15, 2015Allergan, Kythera
According to a notice filed with the state of California, Allergan will be laying off 117 employees at Kythera’s Westlake …
ABPI hits back at Prime Minister’s criticism of high drug prices
October 15, 2015Sales and Marketing ABPI, Drug pricing, Duchenne Muscular Dystrophy, NICE, Translarna, ataluren, david cameron, prime minister, rare disease
The ABPI has responded to comments made by UK Prime Minister David Cameron during yesterday’s Prime Minster’s Questions, in which …
Crescendo Biologics appoints Dr Peter Pack as chief exec
October 15, 2015Business Services, Research and Development
Crescendo Biologics has announced the appointment of Dr Peter Pack as chief executive, who will oversee the company’s new drug …
Novartis and Biogen launch drug access programmes in developing countries
October 15, 2015Manufacturing and Production, Sales and Marketing Biogen, Novartis, access, aid, corporate social responsibility, csr, humanitarian aid
Novartis and Biogen have begun new campaigns aimed at increasing access to medicines in developing countries. The Swiss firm has …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
